HLS — HLS Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$137.60m
- CA$189.89m
- $55.50m
Annual cashflow statement for HLS Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -13.1 | -23.6 | -27.5 | -19.7 | -12.4 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.123 | 3.92 | 9.53 | 2.93 | 6.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -1.98 | 2.08 | 2.55 | -1.8 | 2.65 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | 16.4 | 16.9 | 15.8 | 8 | 17.1 |
| Capital Expenditures | -0.69 | -0.148 | -0.189 | -0.015 | -1.21 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.82 | -10 | 0 | 11.8 | -0.498 |
| Acquisition of Business | |||||
| Change in Net Intangibles | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -4.51 | -10.1 | -0.189 | 11.7 | -1.7 |
| Financing Cash Flow Items | 0 | -0.639 | -1.36 | -1.19 | -1.39 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -11.4 | -6.86 | -14.6 | -23.4 | -21.6 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.567 | -0.456 | 1.23 | -4.5 | -5.73 |